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The crushing of tablets and opening of capsules should not be performed without proper care, as these
actions may adversely affect the pharmaceutical release mechanisms. However, various clinical
circumstances occasionally necessitate these actions. The long-term stability of the commercial formulation
of imidafenacin was confirmed after crushing of tablets. For the safe administration of crushed imidafenacin
tablets, we examined the pharmacokinetics of crushed imidafenacin 0. 1-mg tablet after single oral
administration in healthy men. Plasma concentrations were measured in 6 male volunteers (age, 33.3±
10.6 years) orally administered crushed imidafenacin under fasting conditions. Imidafenacin was rapidly
absorbed and plasma concentrations peaked (Cmax) at 414±108 pg/ml after 1.5 h (Tmax ; median), after
which the drug was rapidly eliminated with a half-life (t1/2) of 2. 8±0. 3 h. Area under the plasma
concentration-time curve (AUC0-10) was 1,680±334 pg･h/ml. There were no significant differences in
Cmax, Tmax and t1/2 between the crushed and tablet medications. Thus, crushing has almost no influence on
the pharmacokinetics of imidafenacin. Consequently, this study was made available as information for
patients requiring crushed anticholinergic agents.
(Hinyokika Kiyo 57 : 677-681, 2011)




















ダフェナシン錠 (0.1 mg) 粉砕単回経口投与時の薬物
動態に関する研究を行った．













しくは血小板成分献血または 200 ml を超えるような





泌尿紀要 57 : 677-681，2011年 677
研究デザインは非盲検，単回投与とした．市販のイ
ミダフェナシン錠 0.1 mg（ 1 錠）を投与直前に乳






























0.1 mg 錠剤投与時のデーターと Mann-Whitney の U
検定を用いて比較した．
なお，本研究は利益相反の開示の項目も含め，宮崎





0 hr 0.5 hr 1 hr 1.5 hr 2 hr 3 hr 4 hr 6 hr 8 hr 10 hr
1 BLQ 59 284 399 298 253 177 118 66.7 44.5
2 BLQ 64.5 328 597 447 292 213 130 82.8 51.8
3 BLQ 105 332 362 311 211 162 93.2 57.3 30.5
4 BLQ 229 274 280 248 192 156 83 50.6 30.6
5 BLQ 240 463 401 380 348 254 175 101 72.7
6 BLQ 147 333 382 335 274 239 121 67.3 42.1
Mean ― 141 336 404 337 262 200 120 71 45.4
SD ― 79.3 67.5 105 69.4 56.6 41.3 32.3 18.3 15.7

















粉砕前のイミダフェナシン 0.1 mg 錠の平均重量は
131.0±0.7 mg で，粉砕後の平均重量は 124.9±2.1




各症例の粉砕イミダフェナシン 0.1 mg を単回投与
した時の血漿中濃度の経時的な推移を Table 1 に，薬
物動態パラメーターを Table 2 にそれぞれ示す．
粉砕イミダフェナシン投与後に血漿中濃度は速やか
に上昇し， 6例中 5例で1.5時間後に 1例のみ 1時間
後に血漿中濃度は最大値を示し，この時の血中濃度の
最低値は 280 pg/ml，最高値は 597 pg/ml であった．
その後血漿中濃度は減少傾向を示した．また，薬物動
態パラメーターをみると，Tmax は 1.4±0.2時間で，
t1/2 は2.8±0.3時間で消失していた．Cmax は 414±
108 pg/ml で，AUC0~10 は 1, 680±334 pg･hr/ml で
あった．
泌尿紀要 57巻 12号 2011年678
Table 2. Pharmacokinetic parameters of imidafe-
nacin after oral administration of crushed






tmax (hr) t1/2 (hr)
AUC0-10
(pg･hr/ml)
1 399 1.5 2.8 1,527
2 597 1.5 3 1,919
3 362 1.5 2.5 1,418
4 280 1.5 2.8 1,301
5 463 1 3.2 2,191
6 382 1.5 2.6 1,733
Mean 414 1.4 2.8 1,680
SD 108 0.2 0.3 334
泌57,12,2-1
Fig. 1. Mean plasma concentration of imidafenacin
after oral administration of crushed
imidafenacin 0.1 mg-tablet in healthy men.





血中濃度の推移を Fig. 1 に示す．20代健康成人男性12
















































動態をみても，Tmax および t1/2 は錠剤投与した場合
とほぼ同様な値を示し，粉砕投与後の Cmax の最大値











































































た．粉砕イミダフェナシン 0.1 mg を単回経口投与で
は，粉砕に伴った血中濃度の急激な上昇はなく，粉砕
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